Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Used in Upper Respiratory Disorders: Overview01:16

Drugs Used in Upper Respiratory Disorders: Overview

319
Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
319
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

528
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
528
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

2.6K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

169
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
169

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Remission in Global Airway Diseases: EUFOREA Consensus Paper.

Allergy·2026
Same author

Reply to: S. N. Katkuri et al. and H. Liu et al. on Early and Sustained Improvements in Sense of Smell With Tezepelumab Treatment in Patients With Chronic Rhinosinusitis With Nasal Polyps (WAYPOINT).

International forum of allergy & rhinology·2026
Same author

Don't Collapse the Wave.

American journal of rhinology & allergy·2026
Same author

Association Between Chronic Ambient Fine Particulate Matter and Recurrence Risk in Sinonasal Inverted Papilloma.

International forum of allergy & rhinology·2026
Same author

Olfactory Function, Caffeine Intake, and Mortality in a Nationally Representative Cohort.

International forum of allergy & rhinology·2026
Same author

Early and Sustained Improvements in Sense of Smell With Tezepelumab Treatment in Patients With Chronic Rhinosinusitis With Nasal Polyps (WAYPOINT).

International forum of allergy & rhinology·2026
Same journal

Clinical Efficacy of Tezepelumab in Moderate-to-Severe Uncontrolled Chronic Rhinosinusitis with Nasal Polyps: A Systematic Review of Randomized Controlled Trials.

American journal of rhinology & allergy·2026
Same journal

Cancer Metastasis to the Sinonasal Cavity: Clinical Characteristics and Survival Analysis in 35 Patients.

American journal of rhinology & allergy·2026
Same journal

Implementation and Outcomes of a Structured Epistaxis Protocol in Hereditary Hemorrhagic Telangiectasia: An Observational Cohort Study from a Multidisciplinary Clinic.

American journal of rhinology & allergy·2026
Same journal

Large-Scale Three-Dimensional CT Mapping of the Frontal Sinus Drainage Pathway: Anatomical Relationships and Surgical Validation.

American journal of rhinology & allergy·2026
Same journal

Comparative Restenosis and Revision Rates of Draf IIB Versus Draf III Frontal Sinusotomy in Chronic Rhinosinusitis: A Meta-Analysis Stratified by Endotype.

American journal of rhinology & allergy·2026
Same journal

Adjuvant Radiotherapy Does Not Improve Overall Survival After Negative Margin Resection of Sinonasal Epithelial-Myoepithelial Carcinoma.

American journal of rhinology & allergy·2026
See all related articles

Related Experiment Video

Updated: Aug 8, 2025

Murine Nasal Lavage Fluid Collection without Blood Contamination
05:12

Murine Nasal Lavage Fluid Collection without Blood Contamination

Published on: July 11, 2025

198

Biologics for Nasal Polyps: Synthesizing Current Recommendations into a Practical Clinical Algorithm.

Neal R Godse1, Anjeni Keswani2, Andrew P Lane3

  • 1Section of Rhinology, Sinus and Skull Base Surgery, Head and Neck Institute, 2569Cleveland Clinic, Cleveland, OH, USA.

American Journal of Rhinology & Allergy
|February 27, 2023
PubMed
Summary
This summary is machine-generated.

Biologic therapies offer new hope for chronic rhinosinusitis with nasal polyps (CRSwNP) patients refractory to traditional treatments. Dupilumab shows significant benefits, guiding new treatment selection algorithms for CRSwNP management.

Keywords:
Th2 inflammationbenralizumabbiologicschronic rhinosinusitis with nasal polypsdupilumabmepolizumabomalizumab

More Related Videos

Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic
09:03

Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic

Published on: November 7, 2020

4.9K
Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human Respiratory Mucosa and Laboratory Processing of Samples
11:54

Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human Respiratory Mucosa and Laboratory Processing of Samples

Published on: January 21, 2018

30.6K

Related Experiment Videos

Last Updated: Aug 8, 2025

Murine Nasal Lavage Fluid Collection without Blood Contamination
05:12

Murine Nasal Lavage Fluid Collection without Blood Contamination

Published on: July 11, 2025

198
Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic
09:03

Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic

Published on: November 7, 2020

4.9K
Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human Respiratory Mucosa and Laboratory Processing of Samples
11:54

Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human Respiratory Mucosa and Laboratory Processing of Samples

Published on: January 21, 2018

30.6K

Area of Science:

  • Immunology
  • Otolaryngology

Background:

  • Chronic rhinosinusitis with nasal polyps (CRSwNP) traditionally treated with medical therapy and surgery.
  • Biologic therapies targeting specific inflammatory pathways represent a new management paradigm for CRSwNP.

Approach:

  • Literature review of studies on biologic agent efficacy for CRSwNP.
  • Development of a clinical decision-making algorithm for CRSwNP biologic treatment selection.

Key Points:

  • Biologics target immunoglobulin E, interleukins, or interleukin receptors in the Th2 inflammatory cascade.
  • Biologic therapy is an option for refractory CRSwNP, surgical intolerance, or comorbid Th2 diseases.
  • Dupilumab demonstrates significant therapeutic benefits across multiple CRSwNP outcomes.

Conclusions:

  • Biologics are a significant advancement in CRSwNP management for patients failing other interventions.
  • Further data is needed on indications, selection, and health economics, but biologics offer symptom relief.